NR 547 CEA Exam & Practice Exam (Chamberlain) |
2026/2027 Edition | 150 Verified Questions - 150 Questions
with Answers
NR 547 CEA Exam 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for the NR 547 course at
Chamberlain University, focusing on the Certified Enterprise Architect (CEA) examination. It contains
150 verified questions that span the full breadth of the curriculum, ensuring thorough coverage of all
critical domains. Each question is accompanied by detailed rationales and explanations to reinforce
understanding and application. This resource is essential for students aiming to excel in the NR 547
CEA exam, providing a robust review of key concepts, frameworks, and best practices. Updated for the
2026/2027 academic year, it reflects the latest guidelines and industry standards.
Key Features:
Foundations of Enterprise Architecture: Principles, frameworks (TOGAF, Zachman), and core concepts
Strategic Alignment: Linking business strategy with IT architecture, value streams, and capability mapping
Architecture Domains: Business, Data, Application, and Technology architecture models
Architecture Development Method (ADM): Phases, iterations, and deliverables in TOGAF ADM
Architecture Content Framework: Artifacts, building blocks, and architecture repository
Enterprise Continuum & Tools: Architecture partitions, solutions, and reference models
Architecture Governance: Board, compliance, contracts, and architecture change management
Architecture Maturity Models: Capability maturity, assessment, and improvement
Risk Management in Architecture: Risk identification, analysis, and mitigation strategies
Stakeholder Management: Communication, engagement, and concerns mapping
Security Architecture: Security frameworks, threat modeling, and risk-driven security
Cloud and Digital Architecture: Cloud service models, migration, and digital transformation
Architecture Project Management: Planning, execution, and monitoring of architecture projects
Case Studies and Practical Scenarios: Real-world applications and exam-style questions
Updates for 2026:
- Updated to reflect the latest TOGAF 10 and CEA exam blueprint changes
- Incorporated new questions on cloud-native architecture and edge computing
- Revised rationales to align with 2026/2027 industry best practices
- Enhanced coverage of security architecture and zero-trust models
- Added practice questions on agile architecture and DevOps integration
Abstract:
The NR 547 CEA Exam & Practice Exam document serves as an indispensable study tool for Chamberlain
University students preparing for the Certified Enterprise Architect (CEA) examination. This edition, tailored for
the 2026/2027 academic year, comprises 150 verified questions that systematically address the entire enterprise
architecture curriculum. The content is organized to mirror the course structure, beginning with foundational
principles and progressing through advanced topics such as architecture governance, security, and digital
transformation. Each question is designed to test not only recall but also application and analysis, with detailed
rationales that explain the correct answer and why distractors are incorrect. The document also includes practice
exams that simulate the actual testing environment, enabling students to assess their readiness and identify areas
for improvement. By integrating current industry standards and the latest guidelines, this resource ensures that
Page 1
,students are well-prepared to achieve a high score and demonstrate mastery in enterprise architecture.
Keywords:
NR 547, CEA Exam, Chamberlain University, Enterprise Architecture, TOGAF, Practice Exam, Verified Questions,
2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is followed by a concise
rationale explaining the underlying concept, and incorrect options are addressed with brief explanations to clarify
common misconceptions. This format reinforces learning and helps students understand the reasoning behind each
correct choice.
Compliance Checklist:
Aligned with Chamberlain University NR 547 course objectives
Reflects the latest CEA exam blueprint and industry standards
All questions verified for accuracy and relevance
Includes rationales and explanations for every answer
Organized by content area for systematic review
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Enterprise 1-20 Principles, frameworks, value, history 13%
Architecture
Strategic Alignment & Business 21-40 Strategy, capability mapping, value streams 13%
Architecture
Architecture Domains & Content 41-60 Business, data, application, technology, 13%
Framework artifacts
Architecture Development 61-80 Phases, iterations, deliverables 13%
Method (ADM)
Architecture Governance & 81-100 Governance, compliance, maturity models 13%
Maturity
Risk, Security, and Emerging 101-120 Risk management, security architecture, 13%
Trends cloud, digital
Project Management & Case 121-150 Planning, execution, real-world scenarios 20%
Studies
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 28
mL/min/1.73m²) presents with persistent hyperglycemia despite metformin and
insulin glargine. Which medication adjustment is most appropriate according to
current KDIGO guidelines?
A. Add canagliflozin to enhance glycemic control and promote weight loss.
B. Discontinue metformin and initiate linagliptin.
C. Increase insulin glargine dose to achieve target HbA1c < 6.5%.
D. Add pioglitazone to improve insulin sensitivity.
Correct Answer: B. Discontinue metformin and initiate linagliptin.
Rationale: KDIGO recommends discontinuing metformin when eGFR < 30 and using
dipeptidyl peptidase-4 inhibitors like linagliptin, which do not require dose adjustment in
renal impairment. SGLT2 inhibitors are not recommended when eGFR < 30. Pioglitazone
carries fluid retention risks, and intensive glycemic targets are not advised in advanced
CKD.
Why Wrong:
A - SGLT2 inhibitors are contraindicated when eGFR is below 30 because of reduced
efficacy and increased risk of adverse effects.
C - Intensive glycemic control (HbA1c < 6.5%) is not recommended in advanced
CKD due to hypoglycemia risk and lack of benefit.
D - Pioglitazone can exacerbate fluid retention and heart failure, which are common in
advanced CKD.
Reference: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 and
minor bleeding. Which management strategy aligns with the 2021 ACC/AHA/ESC
guideline update?
A. Administer 5 mg oral vitamin K and hold warfarin until INR is therapeutic.
B. Administer fresh frozen plasma and prothrombin complex concentrate immediately.
C. Hold warfarin and recheck INR in 24 hours without vitamin K.
D. Give 2 mg intravenous vitamin K and resume warfarin at the same dose once INR is
< 3.
Correct Answer: A. Administer 5 mg oral vitamin K and hold warfarin until INR is
therapeutic.
Rationale: For INR > 4.5 with minor bleeding, guidelines recommend holding warfarin
and giving oral vitamin K (1-5 mg) to expedite INR correction. FFP/PCC is reserved for
life-threatening bleeding. Holding alone is too slow, and IV vitamin K is for major
bleeding or rapid reversal.
Why Wrong:
B - FFP and PCC are indicated for major or life-threatening bleeding, not minor
Page 3
, bleeding with INR 5.2.
C - Holding warfarin alone without vitamin K results in a slow INR decline,
increasing bleeding risk.
D - IV vitamin K is reserved for urgent reversal; oral is preferred for
non-life-threatening cases, and resuming the same warfarin dose is inappropriate
without reassessment.
Reference: ACC/AHA/ESC 2021 Atrial Fibrillation Guidelines
Q3. A 45-year-old female with systemic lupus erythematosus (SLE) presents with
new-onset seizures and acute confusion. Which diagnostic test is most specific for
central nervous system (CNS) lupus?
A. Elevated serum anti-dsDNA antibodies
B. Lumbar puncture with elevated opening pressure
C. MRI showing multiple white matter hyperintensities
D. Positive anti-ribosomal P antibodies in cerebrospinal fluid
Correct Answer: D. Positive anti-ribosomal P antibodies in cerebrospinal fluid
Rationale: Anti-ribosomal P antibodies are associated with CNS lupus, particularly
psychosis and diffuse neuropsychiatric manifestations. They have high specificity for
neuropsychiatric SLE. MRI findings are nonspecific, and anti-dsDNA reflects overall
disease activity, not CNS involvement specifically.
Why Wrong:
A - Anti-dsDNA is a marker of renal and general SLE activity, not specific for CNS
lupus.
B - Elevated opening pressure suggests pseudotumor cerebri or infection, not specific
for CNS lupus.
C - White matter hyperintensities on MRI are common in many conditions and lack
specificity for CNS lupus.
Reference: Lahita, R.G. (2025). Systemic Lupus Erythematosus, 6th Ed., Ch. 12
Q4. A patient with severe asthma is being started on a long-acting muscarinic
antagonist (LAMA). Which statement best reflects the current GINA 2024
recommendations regarding LAMA use?
A. LAMAs are the first-line controller for all patients with mild persistent asthma.
B. LAMAs are recommended as add-on therapy for patients with a history of
exacerbations despite ICS-LABA.
C. LAMAs are contraindicated in asthma due to risk of bronchospasm.
D. LAMAs should replace ICS in patients who are well-controlled on low-dose ICS.
Correct Answer: B. LAMAs are recommended as add-on therapy for patients with a
history of exacerbations despite ICS-LABA.
Page 4
2026/2027 Edition | 150 Verified Questions - 150 Questions
with Answers
NR 547 CEA Exam 2026-150 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for the NR 547 course at
Chamberlain University, focusing on the Certified Enterprise Architect (CEA) examination. It contains
150 verified questions that span the full breadth of the curriculum, ensuring thorough coverage of all
critical domains. Each question is accompanied by detailed rationales and explanations to reinforce
understanding and application. This resource is essential for students aiming to excel in the NR 547
CEA exam, providing a robust review of key concepts, frameworks, and best practices. Updated for the
2026/2027 academic year, it reflects the latest guidelines and industry standards.
Key Features:
Foundations of Enterprise Architecture: Principles, frameworks (TOGAF, Zachman), and core concepts
Strategic Alignment: Linking business strategy with IT architecture, value streams, and capability mapping
Architecture Domains: Business, Data, Application, and Technology architecture models
Architecture Development Method (ADM): Phases, iterations, and deliverables in TOGAF ADM
Architecture Content Framework: Artifacts, building blocks, and architecture repository
Enterprise Continuum & Tools: Architecture partitions, solutions, and reference models
Architecture Governance: Board, compliance, contracts, and architecture change management
Architecture Maturity Models: Capability maturity, assessment, and improvement
Risk Management in Architecture: Risk identification, analysis, and mitigation strategies
Stakeholder Management: Communication, engagement, and concerns mapping
Security Architecture: Security frameworks, threat modeling, and risk-driven security
Cloud and Digital Architecture: Cloud service models, migration, and digital transformation
Architecture Project Management: Planning, execution, and monitoring of architecture projects
Case Studies and Practical Scenarios: Real-world applications and exam-style questions
Updates for 2026:
- Updated to reflect the latest TOGAF 10 and CEA exam blueprint changes
- Incorporated new questions on cloud-native architecture and edge computing
- Revised rationales to align with 2026/2027 industry best practices
- Enhanced coverage of security architecture and zero-trust models
- Added practice questions on agile architecture and DevOps integration
Abstract:
The NR 547 CEA Exam & Practice Exam document serves as an indispensable study tool for Chamberlain
University students preparing for the Certified Enterprise Architect (CEA) examination. This edition, tailored for
the 2026/2027 academic year, comprises 150 verified questions that systematically address the entire enterprise
architecture curriculum. The content is organized to mirror the course structure, beginning with foundational
principles and progressing through advanced topics such as architecture governance, security, and digital
transformation. Each question is designed to test not only recall but also application and analysis, with detailed
rationales that explain the correct answer and why distractors are incorrect. The document also includes practice
exams that simulate the actual testing environment, enabling students to assess their readiness and identify areas
for improvement. By integrating current industry standards and the latest guidelines, this resource ensures that
Page 1
,students are well-prepared to achieve a high score and demonstrate mastery in enterprise architecture.
Keywords:
NR 547, CEA Exam, Chamberlain University, Enterprise Architecture, TOGAF, Practice Exam, Verified Questions,
2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is followed by a concise
rationale explaining the underlying concept, and incorrect options are addressed with brief explanations to clarify
common misconceptions. This format reinforces learning and helps students understand the reasoning behind each
correct choice.
Compliance Checklist:
Aligned with Chamberlain University NR 547 course objectives
Reflects the latest CEA exam blueprint and industry standards
All questions verified for accuracy and relevance
Includes rationales and explanations for every answer
Organized by content area for systematic review
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of Enterprise 1-20 Principles, frameworks, value, history 13%
Architecture
Strategic Alignment & Business 21-40 Strategy, capability mapping, value streams 13%
Architecture
Architecture Domains & Content 41-60 Business, data, application, technology, 13%
Framework artifacts
Architecture Development 61-80 Phases, iterations, deliverables 13%
Method (ADM)
Architecture Governance & 81-100 Governance, compliance, maturity models 13%
Maturity
Risk, Security, and Emerging 101-120 Risk management, security architecture, 13%
Trends cloud, digital
Project Management & Case 121-150 Planning, execution, real-world scenarios 20%
Studies
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 28
mL/min/1.73m²) presents with persistent hyperglycemia despite metformin and
insulin glargine. Which medication adjustment is most appropriate according to
current KDIGO guidelines?
A. Add canagliflozin to enhance glycemic control and promote weight loss.
B. Discontinue metformin and initiate linagliptin.
C. Increase insulin glargine dose to achieve target HbA1c < 6.5%.
D. Add pioglitazone to improve insulin sensitivity.
Correct Answer: B. Discontinue metformin and initiate linagliptin.
Rationale: KDIGO recommends discontinuing metformin when eGFR < 30 and using
dipeptidyl peptidase-4 inhibitors like linagliptin, which do not require dose adjustment in
renal impairment. SGLT2 inhibitors are not recommended when eGFR < 30. Pioglitazone
carries fluid retention risks, and intensive glycemic targets are not advised in advanced
CKD.
Why Wrong:
A - SGLT2 inhibitors are contraindicated when eGFR is below 30 because of reduced
efficacy and increased risk of adverse effects.
C - Intensive glycemic control (HbA1c < 6.5%) is not recommended in advanced
CKD due to hypoglycemia risk and lack of benefit.
D - Pioglitazone can exacerbate fluid retention and heart failure, which are common in
advanced CKD.
Reference: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.2 and
minor bleeding. Which management strategy aligns with the 2021 ACC/AHA/ESC
guideline update?
A. Administer 5 mg oral vitamin K and hold warfarin until INR is therapeutic.
B. Administer fresh frozen plasma and prothrombin complex concentrate immediately.
C. Hold warfarin and recheck INR in 24 hours without vitamin K.
D. Give 2 mg intravenous vitamin K and resume warfarin at the same dose once INR is
< 3.
Correct Answer: A. Administer 5 mg oral vitamin K and hold warfarin until INR is
therapeutic.
Rationale: For INR > 4.5 with minor bleeding, guidelines recommend holding warfarin
and giving oral vitamin K (1-5 mg) to expedite INR correction. FFP/PCC is reserved for
life-threatening bleeding. Holding alone is too slow, and IV vitamin K is for major
bleeding or rapid reversal.
Why Wrong:
B - FFP and PCC are indicated for major or life-threatening bleeding, not minor
Page 3
, bleeding with INR 5.2.
C - Holding warfarin alone without vitamin K results in a slow INR decline,
increasing bleeding risk.
D - IV vitamin K is reserved for urgent reversal; oral is preferred for
non-life-threatening cases, and resuming the same warfarin dose is inappropriate
without reassessment.
Reference: ACC/AHA/ESC 2021 Atrial Fibrillation Guidelines
Q3. A 45-year-old female with systemic lupus erythematosus (SLE) presents with
new-onset seizures and acute confusion. Which diagnostic test is most specific for
central nervous system (CNS) lupus?
A. Elevated serum anti-dsDNA antibodies
B. Lumbar puncture with elevated opening pressure
C. MRI showing multiple white matter hyperintensities
D. Positive anti-ribosomal P antibodies in cerebrospinal fluid
Correct Answer: D. Positive anti-ribosomal P antibodies in cerebrospinal fluid
Rationale: Anti-ribosomal P antibodies are associated with CNS lupus, particularly
psychosis and diffuse neuropsychiatric manifestations. They have high specificity for
neuropsychiatric SLE. MRI findings are nonspecific, and anti-dsDNA reflects overall
disease activity, not CNS involvement specifically.
Why Wrong:
A - Anti-dsDNA is a marker of renal and general SLE activity, not specific for CNS
lupus.
B - Elevated opening pressure suggests pseudotumor cerebri or infection, not specific
for CNS lupus.
C - White matter hyperintensities on MRI are common in many conditions and lack
specificity for CNS lupus.
Reference: Lahita, R.G. (2025). Systemic Lupus Erythematosus, 6th Ed., Ch. 12
Q4. A patient with severe asthma is being started on a long-acting muscarinic
antagonist (LAMA). Which statement best reflects the current GINA 2024
recommendations regarding LAMA use?
A. LAMAs are the first-line controller for all patients with mild persistent asthma.
B. LAMAs are recommended as add-on therapy for patients with a history of
exacerbations despite ICS-LABA.
C. LAMAs are contraindicated in asthma due to risk of bronchospasm.
D. LAMAs should replace ICS in patients who are well-controlled on low-dose ICS.
Correct Answer: B. LAMAs are recommended as add-on therapy for patients with a
history of exacerbations despite ICS-LABA.
Page 4
